This is a rare genetic condition where the body can't properly break down a specific sugar called mannose. This leads to a buildup of mannose in certain parts of the body, causing various health problems. It's usually inherited from parents.
Every report comes from a Lived member, sent anonymously.
Have you had Stem Cell Transplant for Alpha-Mannosidosis?
Alpha-mannosidosis is a rare inherited condition in which the body cannot properly break down certain sugar-containing molecules inside cells. As this material builds up over time, it affects many parts of the body at once: hearing, bones and joints, muscles, the immune system and the brain. Common features include intellectual disability and delayed speech, hearing loss, frequent ear and other infections, skeletal changes such as a curved spine or knock knees, and recognizable facial features such as a large head, prominent forehead and widely spaced teeth. Severity varies widely, even between brothers and sisters. In the rare severe form, problems are obvious in infancy and the disease advances quickly. More often, a baby seems typical at birth and problems emerge gradually through childhood. In the mildest form, signs may not be recognized until after age 10 or even adulthood. The condition affects roughly 1 in 500,000 to 1,000,000 people, so many clinicians never see a case.
Alpha-mannosidosis is caused by variants (changes) in the MAN2B1 gene, which carries the instructions for an enzyme called lysosomal alpha-mannosidase. This enzyme works inside lysosomes, the compartments that break down and recycle material in cells, where it trims sugar chains attached to proteins. When the enzyme is missing or works poorly, these sugar chains (called oligosaccharides) accumulate, cells stop working normally and tissues are gradually damaged. The condition is inherited in an autosomal recessive pattern: a person is affected only when both copies of the gene carry a variant, one from each parent. Parents who each carry one variant usually have no symptoms. When both parents are carriers, each pregnancy has a 25% chance of an affected child and a 50% chance of a child who is an unaffected carrier. A family history of the condition, or parents who are related by blood, makes it more likely. The specific variants a person has do not reliably predict how severe the condition will be.
Clinicians usually suspect alpha-mannosidosis when several problems appear together, such as learning or speech delays, hearing loss, frequent infections, skeletal changes and characteristic facial features. Because each of these is common on its own, the full picture can take years to come together. In one international study of people diagnosed at age 16 or older, the average time from early signs to diagnosis was about 20 years for moderate to severe disease and about 27 years for mild disease. A urine test showing high levels of mannose-rich oligosaccharides, or a blood smear in which some white blood cells contain small empty-looking pockets (vacuoles), can point toward the diagnosis but cannot confirm it. Confirmation comes from measuring alpha-mannosidase activity in white blood cells or skin cells, which is low or absent in affected people, along with genetic testing of the MAN2B1 gene. Once a family's variants are known, relatives can have carrier testing, and a future pregnancy can be tested through chorionic villus sampling or amniocentesis. After diagnosis, a baseline workup usually includes hearing tests, an ear, nose and throat assessment, an eye exam, X-rays of the skeleton and an evaluation of thinking, learning and development, so problems can be addressed before they cause further harm.
There is no cure, and there are no published management guidelines for this rare condition, but treatment can slow some effects of the disease and limit complications. Care is usually led by a metabolic or medical genetics specialist working with hearing, ear, nose and throat, eye, orthopedic, dental, therapy and mental health clinicians. Enzyme replacement therapy supplies a lab-made version of the missing enzyme. Velmanase alfa (Lamzede), approved in the United States in 2023, is given as an intravenous (IV) infusion once a week, on an ongoing basis. It is approved for the effects of the disease outside the brain and spinal cord, because there is no evidence that it reaches the brain well enough to improve thinking or prevent intellectual decline. In the main year-long trial, it clearly lowered the buildup of oligosaccharides in the blood, while gains in stair-climbing, walking and breathing tests were smaller and not statistically certain. In pooled data from people treated for about two and a half years on average, those measures improved. A small study of five children under 6 also found better hearing, antibody levels or quality of life. Allergic-type reactions during infusions are common, and severe reactions including anaphylaxis can occur, so infusions are given where staff can treat them, often after medicines that lower the chance of a reaction. Because it caused birth defects in animal studies, pregnancy is ruled out before starting, and people who could become pregnant use effective contraception during treatment. Hematopoietic stem cell transplantation (a bone marrow or umbilical cord blood transplant) replaces a person's blood-forming cells with donor cells that make the enzyme. In the small number of reported patients, transplants done at a young age helped preserve thinking skills, stabilize bone disease and reduce infections. The trade-off is serious: transplant can cause dangerous infections, graft-versus-host disease (donor immune cells attacking the body) and death, and these risks are higher in older patients. It is mainly considered for young children, before significant decline, after careful discussion with a transplant center. Supportive care matters at every stage. Hearing aids make speech therapy far more effective, and ear tubes can relieve hearing loss caused by repeated fluid in the middle ear. Physical and occupational therapy support movement and daily skills. Orthopedic surgery can correct spine curvature or knock knees (which works best when done early in childhood) and treat badly damaged hips and knees later. Regular dental care, a shunt to drain fluid if it builds up around the brain (hydrocephalus), and treatment of psychiatric symptoms are also part of care.
Apart from the severe infant-onset form, alpha-mannosidosis usually progresses slowly over decades, and many people live into their fifties. Muscle weakness, joint damage and problems with balance and coordination (ataxia) tend to increase through the teens, twenties and thirties, and most adults eventually rely on a wheelchair. Intellectual disability is usually mild to moderate, and many people learn to read, but nearly everyone needs some ongoing support with daily life as an adult. The severe form that starts in infancy advances quickly, and children with it often do not survive childhood. Hearing loss is nearly universal and is a major reason speech develops late, so early hearing support makes a real difference for learning. Infections tend to be most frequent in the first decade of life. More than a quarter of adults have psychiatric symptoms, typically starting in adolescence or early adulthood: episodes of confusion, anxiety, depression or hallucinations that often last 3 to 12 weeks and may be followed by a long period of heavy sleepiness and some loss of skills. Stressors such as surgery, emotional upset or a change in routine can set off an episode, so predictable routines and planning around hospital stays can help. Ongoing care is proactive: regular hearing and eye checks, monitoring of the spine and joints, dental visits, and developmental or neuropsychological assessments, plus weekly infusions for those on enzyme therapy. Families often benefit from early school planning, genetic counseling and support from rare disease organizations.
Ask about testing for alpha-mannosidosis when a child or adult has a combination of hearing loss, learning or speech delays, frequent infections and skeletal or facial differences, especially if a brother or sister has similar problems. Families with a known diagnosis can see a genetics team before a future pregnancy to discuss testing options. Contact the care team soon about a sudden change in behavior, mood or thinking, a young child's head growing faster than expected (a possible sign of fluid building up around the brain), new hip, knee or back pain, worsening walking or balance, or hearing that seems to be getting worse. During an enzyme replacement infusion, tell the staff immediately about trouble breathing, facial swelling, hives, vomiting, feeling faint or a bluish color to the lips or skin. These can be signs of anaphylaxis, which needs emergency treatment right away.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Alpha-Mannosidosis is like, what's helped you, or ask the community a question.